The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Froriep

4 RUE CHARLES-BONNET, CASE POSTALE 399, 1211 GENÈVE 12, SWITZERLAND
Tel:
Work +41 22 839 63 00
Fax:
Fax +41 22 347 71 59
Email:
Web:
www.froriep.com
Geneva, London, Madrid, Zug, Zurich

Main work contacts

CategoryContact
Arbitration Jean Marguerat, Jean-Marie Vulliemin, Franz X Stirnimann, Hubert Orso Gilliéron, Lucien Valloni (+41 44 386 60 00 | lvalloni@froriep.ch), Isabelle Romy (+41 44 386 60 00 | iromy@froriep.ch)
Employment Alain Gros, Julie Wynne, Franz X Stirnimann, Marcel C Steinegger (+41 44 386 60 00 | msteinegger@froriep.ch)
Charity and Social enterprise
Aviation Alain Gros
Corporate and commercial Jean-Luc Herbez, Jérôme de Montmollin, Franz X Stirnimann, Eric Haymann (+41 44 386 60 00 | ehaymann@froriep.ch), Felix M Mathis (+41 44 386 60 00 | fmathis@froriep.ch), Peter J Merz (+41 44 386 60 00 | pmerz@froriep.ch)
Private clients Jean-Luc Herbez, Jean-Marie Vulliemin, Nicolas Junod, Julie Wynne, Eric Haymann (+41 44 386 60 00 | ehaymann@froriep.ch), Oliver Arter (+41 44 386 60 00 | oarter@froriep.ch), Marcel R. Jung (+41 44 386 60 00 | mjung@froriep.ch)
Competition Franz X Stirnimann, Hubert Orso Gilliéron
M&A and transactions Jérôme de Montmollin, Jean-Luc Herbez, Catrina Luchsinger Gähwiler (+41 44 386 60 00 | cluchsinger@froriep.ch)
Banking and finance Jean-Luc Herbez, Jérôme de Montmollin, Laetitia Meier Droz, Catrina Luchsinger Gähwiler (+41 44 386 60 00 | cluchsinger@froriep.ch)
Sports Jean-Marie Vulliemin, Jean Marguerat, Lucien Valloni (+41 44 386 60 00 | lvalloni@froriep.ch)
Litigation Alain Gros, Jean Marguerat, Laetitia Meier Droz, Isabelle Romy (+41 44 386 60 00 | iromy@froriep.ch), Marcel C Steinegger (+41 44 386 60 00 | msteinegger@froriep.ch), Lucien Valloni (+41 44 386 60 00 | lvalloni@froriep.ch), Sabina Schellenberg (+41 44 386 60 00 | sschellenberg@froriep.ch)
Capital markets Franz X Stirnimann, Laetitia Meier Droz, Catrina Luchsinger Gähwiler (+41 44 386 60 00 | cluchsinger@froriep.ch)
Charity and social enterprise Julie Wynne
M&A & Transaction Hubert Orso Gilliéron
Corporate & Commercial Hubert Orso Gilliéron
Art Law
Aviation & Shipping
Banking & Finance
Capital Markets
Charity & Social enterprise
Competition
TMT Nicola Benz (+41 44 386 60 00 | nbenz@froriep.ch)
Corporate & Commercial
Real estate Isabelle Romy (+41 44 386 60 00 | iromy@froriep.ch), Lucien Valloni (+41 44 386 60 00 | lvalloni@froriep.ch)
Data Protection
Disruptive Technologies
Employment
Data protection Nicola Benz (+41 44 386 60 00 | nbenz@froriep.ch)
Insolvency & Restructuring
Tax Marcel R Jung (+41 44 386 60 00 | mjung@froriep.ch)
Intellectual Property
Intellectual property Nicola Benz (+41 44 386 60 00 | nbenz@froriep.ch)
Litigation
M&A & Transactions
Notarial Services
Private Client
Public Commercial Law
Real Estate
Sports Law
Tax
Disruptive technologies Catrina Luchsinger Gähwiler (+41 44 386 60 00 | cluchsinger@froriep.ch), Peter J Merz (+41 44 386 60 00 | pmerz@froriep.ch), Nicola Benz (+41 44 386 60 00 | nbenz@froriep.ch)

Legal Developments by:
Froriep

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Bär & Karrer Awarded "Law Firm of the Year - Switzerland" at the Citywealth Magic Circle Awards 201

    Bär & Karrer is pleased to announce that it has received the award “Law Firm of the Year - Switzerland” at the Citywealth Magic Circle Awards in London. This award recognizes Bär & Karrer as the Swiss law firm with the best private client team.
  • Bär & Karrer Advises Ashcroft on the Acquisition of Rüeger Holding

    Ashcroft Inc., headquartered in Stratford, CT, USA, a subsidiary of Tokyo Stock Exchange listed Nagano Keiki Co., Ltd, has announced the completion of the acquisition of Swiss-based Rüeger Holding SA (Rüeger) and Dutch-based STIKO Meetapparentenfabriek B.V. (Stiko), both manufacturers of specialty temperature and pressure measurement products, from their previous owners, Bernard and Jean-Marc Rüeger.
  • Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

    Click here for more information.
  • Bär & Karrer Advises B3i in its Current Equity Funding Round

    Industry-led InsurTech B3i Services AG successfully raised additional funds from current shareholders and new investors to further develop and grow its blockchain-based insurance transaction platform. B3i was founded in October 2016 as an insurance industry consortium which then formed B3i Services AG as an independent company. The shareholder group includes some of the world's largest insurers and reinsurers from across Europe, the Americas, and Asia. B3i intends to further expand its shareholder base over the next several months.
  • Bär & Karrer Continues to Grow Finance and Sports Practice with Two New Partners

    Bär & Karrer is pleased to announce that it further strengthens its Financing and Sports practices with new partners Lukas Roesler and Dr. Jan Kleiner, both of whom have worked with the firm previously.
  • Bär & Karrer Advises Novartis and Alcon on the Spin-off of Alcon

    Today, Novartis AG completed the spin-off of the Alcon eye care devices business, and Alcon Inc. debuted as independent publicly traded company. The Alcon shares were successfully listed on the SIX Swiss Exchange Ltd. and the New York Stock Exchange. They are also included in the Swiss Market Index (SMI), which comprises the 20 largest Swiss listed stocks.
  • Bär & Karrer Advises Primeo Energie and CSA Energie-Infrastructure Schweiz in Aquisition from Elét

    Primeo Energie, EOS Holding SA (EOS) and Électricité de France (EDF) have entered into a share purchase agreement relating to the purchase by Primeo Energie and EOS of the 25% interest held by EDF in Alpiq Holding SA. The purchase by Primeo Eergie and EOS will be financed through mandatory exchangeable loan agreements made by CSA Energie-Infrastruktur Schweiz (CSA) as lender, the biggest investment pool for Swiss energy infrastructure with 135 Swiss pension funds acting as investors. At maturity the mandatory exchangeable loan agreements will be converted into shares in Alpiq. Primeo Energie and EOS thereby pave the way for a Swiss shareholder structure of Alpiq.
  • Bär & Karrer Awarded Most Innovative Swiss Law Firm of the Year at the IFLR Europe Awards

    Bär & Karrer was awarded „Most innovative law firm of the year - Switzerland", the national award for Switzerland given in the IFLR European Awards. The most innovative law firm of the year award recognizes Bär & Karrer as the Swiss law firm with the best track record in 2018 giving advice on the most innovative cross-border deals covering all award practice areas. It is already the third prize of this kind in period of six years awarded to Bär & Karrer.
  • Bär & Karrer Advises DSV on Public Exchange Offer for Panalpina

    On 1 April 2019, DSV A/S, Hedehusene, Denmark and Panalpina Welttransport (Holding) AG, Zurich, Switzerland, have entered into an agreement on the terms and conditions of a combination by way of a public exchange offer by DSV for all publicly held registered shares of Panalpina for approximately CHF 4.6 billion. The board of directors of Panalpina has resolved to support the public exchange offer by DSV and to recommend the acceptance of DSV's public exchange offer to its shareholders.
  • Bär & Karrer Advises Lonza on the Entering into a Strategic Joint Venture with Chr. Hansen for Deve

    On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in Hørsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.